Antidepressant drug-drug interactions: Clinical relevance and risk management

Charles Nemeroff, Sheldon H. Preskorn, C. Lindsay DeVane

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Multiple medication use is a common phenomenon, especially in patients with comorbid conditions and those treated with psychiatric drugs such as antidepressants. Combination treatment may result in potentially harmful drug-drug interactions (DDIs). Results of DDIs range from nuisance side effects to serious adverse consequences. DDIs may also result in improved efficacy. Augmentation strategies, for example, are intentional therapeutic DDIs. Pharmacokinetic DDIs occur when a second drug alters the absorption, distribution, metabolism, or clearance of the first drug. Research has concentrated on the relative effects of antidepressants on cytochrome P450 enzymes and, more recently, on drug transporters as potential mediators of clinically important pharmacokinetic DDIs. The most common, clinically relevant pharmacokinetic DDIs involve alteration in oxidative drug metabolism. Pharmacodynamic DDIs occur when the effects of a second drug quantitatively or qualitatively alters those of the first drug. Pharmacodynamic DDIs are not typically studied in vivo because of the potential for a serious adverse effect. All antidepressants can interact pharmacodynamically with certain other drugs. The risk of harmful DDIs can be reduced by recognizing variables that affect dose-concentration-effect relationships. It is important for physicians to weigh the risks and benefits of potential DDIs against the risks that accompany timid or ineffective disease treatment.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalCNS Spectrums
Volume12
Issue numberSUPPL. 7
StatePublished - May 1 2007
Externally publishedYes

Fingerprint

Risk Management
Drug Interactions
Antidepressive Agents
Pharmaceutical Preparations
Pharmacokinetics
Cytochrome P-450 Enzyme System

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology

Cite this

Antidepressant drug-drug interactions : Clinical relevance and risk management. / Nemeroff, Charles; Preskorn, Sheldon H.; DeVane, C. Lindsay.

In: CNS Spectrums, Vol. 12, No. SUPPL. 7, 01.05.2007, p. 1-11.

Research output: Contribution to journalArticle

Nemeroff, C, Preskorn, SH & DeVane, CL 2007, 'Antidepressant drug-drug interactions: Clinical relevance and risk management', CNS Spectrums, vol. 12, no. SUPPL. 7, pp. 1-11.
Nemeroff, Charles ; Preskorn, Sheldon H. ; DeVane, C. Lindsay. / Antidepressant drug-drug interactions : Clinical relevance and risk management. In: CNS Spectrums. 2007 ; Vol. 12, No. SUPPL. 7. pp. 1-11.
@article{022758f8d61a4f58a86d85e43f2963b5,
title = "Antidepressant drug-drug interactions: Clinical relevance and risk management",
abstract = "Multiple medication use is a common phenomenon, especially in patients with comorbid conditions and those treated with psychiatric drugs such as antidepressants. Combination treatment may result in potentially harmful drug-drug interactions (DDIs). Results of DDIs range from nuisance side effects to serious adverse consequences. DDIs may also result in improved efficacy. Augmentation strategies, for example, are intentional therapeutic DDIs. Pharmacokinetic DDIs occur when a second drug alters the absorption, distribution, metabolism, or clearance of the first drug. Research has concentrated on the relative effects of antidepressants on cytochrome P450 enzymes and, more recently, on drug transporters as potential mediators of clinically important pharmacokinetic DDIs. The most common, clinically relevant pharmacokinetic DDIs involve alteration in oxidative drug metabolism. Pharmacodynamic DDIs occur when the effects of a second drug quantitatively or qualitatively alters those of the first drug. Pharmacodynamic DDIs are not typically studied in vivo because of the potential for a serious adverse effect. All antidepressants can interact pharmacodynamically with certain other drugs. The risk of harmful DDIs can be reduced by recognizing variables that affect dose-concentration-effect relationships. It is important for physicians to weigh the risks and benefits of potential DDIs against the risks that accompany timid or ineffective disease treatment.",
author = "Charles Nemeroff and Preskorn, {Sheldon H.} and DeVane, {C. Lindsay}",
year = "2007",
month = "5",
day = "1",
language = "English",
volume = "12",
pages = "1--11",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "SUPPL. 7",

}

TY - JOUR

T1 - Antidepressant drug-drug interactions

T2 - Clinical relevance and risk management

AU - Nemeroff, Charles

AU - Preskorn, Sheldon H.

AU - DeVane, C. Lindsay

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Multiple medication use is a common phenomenon, especially in patients with comorbid conditions and those treated with psychiatric drugs such as antidepressants. Combination treatment may result in potentially harmful drug-drug interactions (DDIs). Results of DDIs range from nuisance side effects to serious adverse consequences. DDIs may also result in improved efficacy. Augmentation strategies, for example, are intentional therapeutic DDIs. Pharmacokinetic DDIs occur when a second drug alters the absorption, distribution, metabolism, or clearance of the first drug. Research has concentrated on the relative effects of antidepressants on cytochrome P450 enzymes and, more recently, on drug transporters as potential mediators of clinically important pharmacokinetic DDIs. The most common, clinically relevant pharmacokinetic DDIs involve alteration in oxidative drug metabolism. Pharmacodynamic DDIs occur when the effects of a second drug quantitatively or qualitatively alters those of the first drug. Pharmacodynamic DDIs are not typically studied in vivo because of the potential for a serious adverse effect. All antidepressants can interact pharmacodynamically with certain other drugs. The risk of harmful DDIs can be reduced by recognizing variables that affect dose-concentration-effect relationships. It is important for physicians to weigh the risks and benefits of potential DDIs against the risks that accompany timid or ineffective disease treatment.

AB - Multiple medication use is a common phenomenon, especially in patients with comorbid conditions and those treated with psychiatric drugs such as antidepressants. Combination treatment may result in potentially harmful drug-drug interactions (DDIs). Results of DDIs range from nuisance side effects to serious adverse consequences. DDIs may also result in improved efficacy. Augmentation strategies, for example, are intentional therapeutic DDIs. Pharmacokinetic DDIs occur when a second drug alters the absorption, distribution, metabolism, or clearance of the first drug. Research has concentrated on the relative effects of antidepressants on cytochrome P450 enzymes and, more recently, on drug transporters as potential mediators of clinically important pharmacokinetic DDIs. The most common, clinically relevant pharmacokinetic DDIs involve alteration in oxidative drug metabolism. Pharmacodynamic DDIs occur when the effects of a second drug quantitatively or qualitatively alters those of the first drug. Pharmacodynamic DDIs are not typically studied in vivo because of the potential for a serious adverse effect. All antidepressants can interact pharmacodynamically with certain other drugs. The risk of harmful DDIs can be reduced by recognizing variables that affect dose-concentration-effect relationships. It is important for physicians to weigh the risks and benefits of potential DDIs against the risks that accompany timid or ineffective disease treatment.

UR - http://www.scopus.com/inward/record.url?scp=34249783464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249783464&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34249783464

VL - 12

SP - 1

EP - 11

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - SUPPL. 7

ER -